Zacks: Brokerages Expect Prevail Therapeutics Inc. (NASDAQ:PRVL) Will Post Earnings of -$0.64 Per Share

Share on StockTwits

Wall Street brokerages predict that Prevail Therapeutics Inc. (NASDAQ:PRVL) will announce ($0.64) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Prevail Therapeutics’ earnings, with estimates ranging from ($0.65) to ($0.63). The company is scheduled to report its next quarterly earnings report on Tuesday, March 31st.

According to Zacks, analysts expect that Prevail Therapeutics will report full year earnings of ($2.88) per share for the current year, with EPS estimates ranging from ($3.55) to ($2.34). For the next year, analysts expect that the company will report earnings of ($2.77) per share, with EPS estimates ranging from ($3.15) to ($2.30). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Prevail Therapeutics.

A number of research analysts have recently weighed in on the stock. Citigroup assumed coverage on shares of Prevail Therapeutics in a research note on Thursday, March 5th. They set a “buy” rating and a $24.00 price objective for the company. Oppenheimer assumed coverage on shares of Prevail Therapeutics in a research note on Tuesday, February 18th. They set an “outperform” rating and a price objective for the company. BidaskClub cut shares of Prevail Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 15th. Wedbush reissued an “outperform” rating and set a $19.00 price objective (down from $20.00) on shares of Prevail Therapeutics in a research note on Thursday. Finally, Zacks Investment Research cut shares of Prevail Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 29th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $19.00.

A number of hedge funds have recently added to or reduced their stakes in the business. Fred Alger Management LLC purchased a new stake in shares of Prevail Therapeutics during the 4th quarter valued at $47,000. Bank of New York Mellon Corp grew its stake in shares of Prevail Therapeutics by 1.6% during the 4th quarter. Bank of New York Mellon Corp now owns 213,490 shares of the company’s stock valued at $3,380,000 after buying an additional 3,419 shares during the period. Citigroup Inc. grew its stake in shares of Prevail Therapeutics by 965.4% during the 4th quarter. Citigroup Inc. now owns 4,123 shares of the company’s stock valued at $65,000 after buying an additional 3,736 shares during the period. Barclays PLC grew its stake in shares of Prevail Therapeutics by 98.9% during the 4th quarter. Barclays PLC now owns 7,564 shares of the company’s stock valued at $119,000 after buying an additional 3,761 shares during the period. Finally, Tower Research Capital LLC TRC purchased a new stake in shares of Prevail Therapeutics during the 4th quarter valued at $67,000. 79.08% of the stock is owned by hedge funds and other institutional investors.

Shares of PRVL opened at $12.00 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 17.05 and a quick ratio of 17.05. The firm has a 50 day simple moving average of $15.27 and a 200-day simple moving average of $14.19. Prevail Therapeutics has a 1-year low of $7.41 and a 1-year high of $19.25.

About Prevail Therapeutics

Prevail Therapeutics Inc, a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The company's lead product candidate is PR001 for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease.

Further Reading: Why Invest in Dividend Achievers?

Get a free copy of the Zacks research report on Prevail Therapeutics (PRVL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Prevail Therapeutics (NASDAQ:PRVL)

Receive News & Ratings for Prevail Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prevail Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Mitchell Mcleod Pugh & Williams Inc. Has $252,000 Holdings in General Electric
Mitchell Mcleod Pugh & Williams Inc. Has $252,000 Holdings in General Electric
Mitchell Mcleod Pugh & Williams Inc. Acquires 500 Shares of Starbucks Co.
Mitchell Mcleod Pugh & Williams Inc. Acquires 500 Shares of Starbucks Co.
Bank of America  PT Lowered to $20.00 at UBS Group
Bank of America PT Lowered to $20.00 at UBS Group
IFM Investors Pty Ltd Sells 5,253 Shares of Walmart Inc
IFM Investors Pty Ltd Sells 5,253 Shares of Walmart Inc
Macquarie Group Ltd. Has $2.83 Million Position in Valero Energy Co.
Macquarie Group Ltd. Has $2.83 Million Position in Valero Energy Co.
Marquette Asset Management LLC Increases Stock Position in Boeing Co
Marquette Asset Management LLC Increases Stock Position in Boeing Co


© 2006-2020 Ticker Report